[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526077":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":37,"responsibleParty":50,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of Rome Tor Vergata","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"OLT",null,"Observation of MR-proADM levels at protocol timepoints to predict main (DGF and AR) and secondary (surgical complications, infections, others) complications after liver transplantation at our Institution.",[13],"Biological: MR-proADM dosage",{"label":15,"type":10,"description":16,"interventionNames":17},"KT","Observation of MR-proADM levels at protocol timepoints to predict main (DGF and AR) and secondary (surgical complications, urological complications, infections, others) complications after kidney transplantation at our Institution.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"BIOLOGICAL","MR-proADM dosage","Dosage of MR proADM at OLT\u002FKT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U",[15,9],[25],{"name":26,"affiliation":5,"role":27},"Roberta Angelico, PhD FEBS","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","0620908294","roberta.angelico@med.uniroma2.it",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Domiziana Pedini, MD","+393488869569","domiziana.pedini@libero.it",[38],{"facility":5,"status":39,"city":40,"state":10,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":10},"RECRUITING","Rome","00133","Italy","IT",{"type":45,"coordinates":46},"Point",[47,48],12.51133,41.89193,{"lat":48,"lon":47},{"type":27,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Roberta Angelico","Associate Professor, MD, PhD, FEBS","100526077","mr-proadm-as-a-early-biomarker-for-dgf-and-ar-in-kidney-and-liver-transplantation-100526077",false,"NCT06130046","MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation","DARE","Inclusion Criteria:\n\n* Kidney transplant recipient at our Institution\n* Liver transplant recipient at our Institution\n\nExclusion Criteria:\n\n* Re-transplantation\n* Dual kidney transplantation\n* Combined transplant (kidney-liver, kidney-pancreas)\n* Autoimmune disease as indication to transplant","ALL","18 Years","70 Years",{"count":64,"type":65},300,"ESTIMATED","OBSERVATIONAL","To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.",[69,70],"Kidney Transplant; Complications","Liver Transplant; Complications",[72,73,74,75,76,77],"MR-proADM","Adrenomedullin","Kidney Transplantation","Liver Transplantation","DGF","Acute rejection","2025-07-29",{"date":80,"type":81},"2025-08-01","ACTUAL",{"date":83,"type":81},"2022-12-01",{"date":85,"type":65},"2026-12-01",{"name":5,"class":6},1]